ARGENICA THERAPEUTICS LIMITED — Investor Relations & Filings

Argenica Therapeutics Limited is a clinical-stage company focused on developing novel neuroprotective therapeutics to minimize brain tissue death following acute neurological injury. The company's lead drug candidate, ARG-007, is a cationic arginine-rich peptide engineered to inhibit multiple cell death pathways. ARG-007 is being developed for applications in ischemic stroke, traumatic brain injury, and hypoxic-ischaemic encephalopathy. The therapeutic is designed for rapid administration by first responders, aiming to protect brain cells during the critical window following an injury. By addressing the neurodegenerative cascade, the company seeks to improve long-term clinical outcomes for patients suffering from stroke and other forms of brain trauma.